BioSpace News Archive

Leverages proprietary pan-amyloid targeting agents with potential to diagnose and reverse the underlying pathology of systemic amyloid diseases, including AL and ATTR amyloidosis [14-September-2020] SOUTH SAN FRANCISCO, Calif. , Sept. 14, 2020 /PRNewswire/ -- Attralus, a biopharmaceutical company focused on creating transformative medicines to improve the lives of pat

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Wednesday, September 16, 2020 under the Company’s current trading symbol, “APLI.” “Graduating to the premier exchange for Canadian equiti

First site initiated for enrollment in the Netherlands Regulatory approval granted to start trial in Germany Additional sites to be added in the US, EU and other regions Encouraging Phase II data accepted for publication in The Lancet Rheumatology JENA, Germany, Sept. 14, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the start of the global Phase III

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced that Joseph Truitt , Chief Executive Officer, will present at the virtual O

Biotech veterans appointed to key executive positions Former CEO of NICE joins as advisor

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Board of Directors of the Company appointed Mr. Patrick G. LePore to serve as a director of the Company, effective as of September 10, 2020.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a Common Stock Purchase Agreement (the “Agreement”) providing for the sale of up to $20 million of common stock to Aspire Capital Fund, LLC,

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), today announced that Caelum Biosciences, Inc. (“Caelum”), in collaboration with Alexion Pharmaceuticals, Inc. (“Alexion”), initiated the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101,

New Allograft Expands to Twice its Size and Provides a Protective Structure to Support the Wound Healing Cascade

- Results presented at the 33rd ECNP Congress from a 12-week, placebo-controlled Phase II trial demonstrated BI 425809 met its primary endpoint - Trial results, together with an ongoing combination Phase II study of BI 425809 and adjunctive computerized cognitive training, add to the body of evidence for Boehringer Ingelheim’s schizophrenia research program - Cognitive impairment associated with schizophrenia (CIAS) has a significant negative impact on daily functioning and r